Wealth Management Partners’s Summit Therapeutics SMMT Stock Holding History

Wealth Management Partners’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.3M	Buy	89,274 +25,490	+40%	+$452K	0.31%	64
2026 Q1	$1.21M	Buy	63,784 +4,354	+7%	+$70.4K	0.35%	63
2025 Q4	$1.04M	Sell	59,430 -15,140	-20%	-$285K	0.3%	69
2025 Q3	$1.54M	Sell	74,570 -1,042	-1%	-$25.3K	0.49%	44
2025 Q2	$1.71M	Sell	75,612 -20,671	-21%	-$471K	0.6%	37
2025 Q1	$1.86M	Sell	96,283 -1,100	-1%	-$22.1K	0.86%	29
2024 Q4	$1.74M	Buy	97,383 +9,000	+10%	+$174K	0.75%	29
2024 Q3	$1.94M	Buy	88,383 +46,383	+110%	+$649K	0.9%	28
2024 Q2	$328K	Sell	42,000 -2,000	-5%	-$10.8K	0.16%	80
2024 Q1	$182K	Buy	44,000 +29,000	+193%	+$115K	0.09%	117
2023 Q4	$39.1K	Buy	+15,000	New	+$30.9K	0.02%	118

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Wealth Management Partners's SMMT Position: Q2 2026 in Review

Wealth Management Partners increased its Summit Therapeutics (SMMT) stake by 40% in Q2 2026, buying an estimated $452K and bringing the position to 89,274 shares worth $1.3M. The position accounts for 0.31% of the portfolio, ranked #64.

Wealth Management Partners first reported a position in SMMT in Q4 2023 and has held it in 11 quarters since. The position peaked at $1.94M in Q3 2024. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

Wealth Management Partners held 89,274 shares of Summit Therapeutics worth $1.3M as of Q2 2026.
Wealth Management Partners bought 25,490 Summit Therapeutics shares in Q2 2026, an estimated $452K.
Summit Therapeutics made up 0.31% of Wealth Management Partners's portfolio in Q2 2026, its #64 holding.
Wealth Management Partners first reported a position in Summit Therapeutics in Q4 2023 and has held it in 11 quarters since.
Wealth Management Partners's Summit Therapeutics position peaked at $1.94M in Q3 2024.
242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Wealth Management Partners's 13F filing for Q2 2026, filed 22 Jul 2026.